Cargando…

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVES: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon 12 and MPL W515K/L, besides chromosomal abno...

Descripción completa

Detalles Bibliográficos
Autores principales:	dos Santos, Leonardo Caires, Ribeiro, Juliana Corrêa da Costa, Silva, Neusa Pereira, Cerutti, Janete, da Silva, Maria Regina Regis, Chauffaille, Maria de Lourdes Lopes Ferrari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia e Hemoterapia 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459377/ https://www.ncbi.nlm.nih.gov/pubmed/23049357 http://dx.doi.org/10.5581/1516-8484.20110116

Ejemplares similares

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
por: Mejía-Ochoa, Mónica, et al.
Publicado: (2019)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Agarwal, M. B., et al.
Publicado: (2015)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
por: Pimpinelli, Fulvia, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
por: Yoon, Seug Yun, et al.
Publicado: (2023)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
por: Fei, Naomi, et al.
Publicado: (2017)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post‐polycythemia vera myelofibrosis
por: Kiso, Shohei, et al.
Publicado: (2016)

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
por: Pósfai, Éva, et al.
Publicado: (2016)

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
por: Accurso, Vincenzo, et al.
Publicado: (2020)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
por: Tefferi, A, et al.
Publicado: (2010)

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
por: Tang, Guilin, et al.
Publicado: (2017)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Progression of primary myelofibrosis to polycythemia vera: A case report
por: Guo, Yan, et al.
Publicado: (2017)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations
por: Jang, Mi-Ae, et al.
Publicado: (2020)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
por: Sobieralski, Patryk, et al.
Publicado: (2023)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
por: Sureau, Léa, et al.
Publicado: (2022)

Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review
por: Li, Li, et al.
Publicado: (2023)

Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
por: Song, Jinming, et al.
Publicado: (2017)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
por: Dold, Leona, et al.
Publicado: (2021)

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT
por: Mora, B., et al.
Publicado: (2022)

Hereditary hemochromatosis and JAK2‐positive polycythemia vera
por: Radwan, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2mkihdp90jcmodsmgti95gurq